Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 23

  • 844 clinical trials
  • 268 recruiting
  • 353 conditions
  • 25 countries

Conditions in this area

353 conditions with trials, the busiest first

Dermatitis atopic88Malignant melanoma79Systemic lupus erythematosus61Psoriasis53Hidradenitis47Psoriatic arthropathy46Systemic scleroderma39Metastatic malignant melanoma32Vitiligo23Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis15Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Diabetic foot13Basal cell carcinoma12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+329

Clinical trials in Skin and subcutaneous tissue disorders

844 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

844 clinical trials

Cutibacterium acnes infection

Recruiting

Study on Reducing Cutibacterium acnes in Shoulder Surgery for Men Using Benzoyl Peroxide and Ethanol-Povidone Iodine Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Povidone, Iodinated
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Acarodermatitis

Recruiting

Study on Treating Scabies with Permethrin and Ivermectin for Patients with Scabies

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ivermectin
  • Sponsor:INFECTOPHARM Arzneimittel und Consilium GmbH

Systemic scleroderma

Recruiting

Study on Mesenchymal Stem Cells for Patients with Systemic Sclerosis and Digital Ulcers

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Human Mesenchymal Stem Cells
  • Sponsor:Universitair Medisch Centrum Utrecht

Ehlers-Danlos syndrome+4

Recruiting

Study on Valsartan for Slowing Aortic Root Dilatation in Children and Young Adults with Marfan Syndrome and Related Conditions

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Valsartan
  • Sponsor:Medical University Of Gdansk

Systemic lupus erythematosus+1

Not yet recruiting

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Psoriasis

Not yet recruiting

Long-term Safety and Efficacy of ORKA-001 in Adults with Moderate-to-Severe Plaque Psoriasis (Open-Label Extension Study)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Papulopustular rosacea

Not yet recruiting

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not yet recruiting

A Phase 2b Study Evaluating the Efficacy and Safety of ENV-294 in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years

Hidradenitis

Not yet recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the effectiveness and safety of JNJ-88545223 in people with active psoriatic arthritis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Janssen Cilag International

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.